Connection | Profiles RNS

The University of Chicago

Login to edit your profile (add a photo, awards, links to other websites, etc.)

Search Result Details

Back to Search Results

This page shows the details of why an item matched the keywords from your search.

Search Results

A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.

One or more keywords matched the following properties of A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.

Property	Value
has major subject area list	Antibodies, Monoclonal; Carcinoma; Fallopian Tube Neoplasms; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms

Search Criteria

Fallopian Tube Cancer